Targeting epigenetic regulation of mir-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Nalls, Dara ^a   Tang, Su Ni ^b   Rodova, Marianna ^a,b   Srivastava, Rakesh K ^b,c   Shankar, Sharmila ^a,c  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KANSAS CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CASPASE 3; CASPASE 7; CELL PROTEIN; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MICRORNA; MICRORNA 34A; NERVE CELL ADHESION MOLECULE; NOTCH RECEPTOR; PROTEIN BCL 2; PROTEIN P53; PROTEIN ZEB 1; PUMA PROTEIN; SIRTUIN 1; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; UNCLASSIFIED DRUG; UVOMORULIN; VORINOSTAT; AZACITIDINE; HYDROXAMIC ACID; MIRN34 MICRORNA, HUMAN;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CANCER STEM CELL; CELL CYCLE ARREST; CELL RENEWAL; CHROMATIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENE FUNCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MIGRATION INHIBITION; MITOSIS INHIBITION; PANCREAS CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; CELL CYCLE; CELL MOTION; CELL PROLIFERATION; DRUG EFFECT; DRUG SCREENING; GENETIC EPIGENESIS; GENETICS; METABOLISM; MULTICELLULAR SPHEROID; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE; UPREGULATION;

GASTROPODA;

APOPTOSIS; AZACITIDINE; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHROMATIN; EPIGENESIS, GENETIC; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXAMIC ACIDS; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; SPHEROIDS, CELLULAR; TUMOR STEM CELL ASSAY; UP-REGULATION;

EID: 80052316514     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024099     Document Type: Article

References (52)

1. Li J, Wientjes MG, Au JL, (2010) Pancreatic cancer: pathobiology, treatment options, and drug delivery. AAPS J 12: 223-232.
2. Inui M, Martello G, Piccolo S, (2010) MicroRNA control of signal transduction. Nat Rev Mol Cell Biol 11: 252-263.
3. Sharma S, Kelly TK, Jones PA, (2010) Epigenetics in cancer. Carcinogenesis 31: 27-36.
4. Schickel R, Boyerinas B, Park SM, Peter ME, (2008) MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 27: 5959-5974.
5. Bandres E, Agirre X, Ramirez N, Zarate R, Garcia-Foncillas J, (2007) MicroRNAs as cancer players: potential clinical and biological effects. DNA Cell Biol 26: 273-282.
6. Garzon R, Calin GA, Croce CM, (2009) MicroRNAs in Cancer. Annu Rev Med 60: 167-179.
7. Lee YS, Dutta A, (2009) MicroRNAs in cancer. Annu Rev Pathol 4: 199-227.
8. Baranwal S, Alahari SK, (2010) miRNA control of tumor cell invasion and metastasis. Int J Cancer 126: 1283-1290.
9. Voorhoeve PM, (2010) MicroRNAs: Oncogenes, tumor suppressors or master regulators of cancer heterogeneity? Biochim Biophys Acta 1805: 72-86.
10. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA, (2009) MicroRNAs-the micro steering wheel of tumour metastases. Nat Rev Cancer 9: 293-302.
11. Waldman SA, Terzic A, (2007) Translating MicroRNA discovery into clinical biomarkers in cancer. JAMA 297: 1923-1925.
12. Wang J, Chen J, Chang P, LeBlanc A, Li D, et al. (2009) MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila Pa) 2: 807-813.
13. Bartels CL, Tsongalis GJ, (2009) MicroRNAs: novel biomarkers for human cancer. Clin Chem 55: 623-631.
14. Bartels CL, Tsongalis GJ, (2010) [MicroRNAs: novel biomarkers for human cancer]. Ann Biol Clin (Paris) 68: 263-272.
15. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, et al. (2010) Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 70: 5923-5930.
16. Croce CM, Calin GA, (2005) miRNAs, cancer, and stem cell division. Cell 122: 6-7.
17. Shankar S, Nall D, Tang SN, Meeker D, Passarini J, et al. (2011) Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS One 6: e16530.
18. Li C, Lee CJ, Simeone DM, (2009) Identification of human pancreatic cancer stem cells. Methods Mol Biol 568: 161-173.
19. Immervoll H, Hoem D, Sakariassen PO, Steffensen OJ, Molven A, (2008) Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer 8: 48.
20. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, et al. (2007) Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 26: 745-752.
21. Morton JP, Klimstra DS, Mongeau ME, Lewis BC, (2008) Trp53 deletion stimulates the formation of metastatic pancreatic tumors. Am J Pathol 172: 1081-1087.
22. Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, et al. (2010) Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A 107: 246-251.
23. Bergan A, Gladhaug IP, Schjolberg A, Bergan AB, Clausen OP, (2000) p53 accumulation confers prognostic information in resectable adenocarcinomas with ductal but not with intestinal differentiation in the pancreatic head. Int J Oncol 17: 921-926.
24. Hu YX, Watanabe H, Ohtsubo K, Yamaguchi Y, Ha A, et al. (1999) Bcl-2 expression related to altered p53 protein and its impact on the progression of human pancreatic carcinoma. Br J Cancer 80: 1075-1079.
25. Kawahira H, Kobayashi S, Kaneko K, Asano T, Ochiai T, (2000) p53 protein expression in intraductal papillary mucinous tumors (IPMT) of the pancreas as an indicator of tumor malignancy. Hepatogastroenterology 47: 973-977.
26. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, et al. (2007) Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 26: 731-743.
27. Welch C, Chen Y, Stallings RL, (2007) MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 26: 5017-5022.
28. Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, et al. (2008) Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 7: 2591-2600.
29. Chim CS, Wong KY, Qi Y, Loong F, Lam WL, et al. (2010) Epigenetic inactivation of the miR-34a in hematological malignancies. Carcinogenesis 31: 745-750.
30. Corney DC, Hwang CI, Matoso A, Vogt M, Flesken-Nikitin A, et al. (2010) Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res 16: 1119-1128.
31. He L, He X, Lowe SW, Hannon GJ, (2007) microRNAs join the p53 network-another piece in the tumour-suppression puzzle. Nat Rev Cancer 7: 819-822.
32. Mullendore ME, Koorstra JB, Li YM, Offerhaus GJ, Fan X, et al. (2009) Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Clin Cancer Res 15: 2291-2301.
33. De La OJ, Murtaugh LC, (2009) Notch signaling: where pancreatic cancer and differentiation meet? Gastroenterology 136: 1499-1502.
34. Yoon K, Gaiano N, (2005) Notch signaling in the mammalian central nervous system: insights from mouse mutants. Nat Neurosci 8: 709-715.
35. Bray SJ, (2006) Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol 7: 678-689.
36. Iso T, Kedes L, Hamamori Y, (2003) HES and HERP families: multiple effectors of the Notch signaling pathway. J Cell Physiol 194: 237-255.
37. Basak O, Taylor V, (2007) Identification of self-replicating multipotent progenitors in the embryonic nervous system by high Notch activity and Hes5 expression. Eur J Neurosci 25: 1006-1022.
38. Takebe N, Harris PJ, Warren RQ, Ivy SP, (2011) Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 8: 97-106.
39. Katoh M, (2006) Notch ligand, JAG1, is evolutionarily conserved target of canonical WNT signaling pathway in progenitor cells. Int J Mol Med 17: 681-685.
40. Wang Z, Li Y, Ahmad A, Banerjee S, Azmi AS, et al. (2011) Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol 8: 27-33.
41. O'Rourke JR, Swanson MS, Harfe BD, (2006) MicroRNAs in mammalian development and tumorigenesis. Birth Defects Res C Embryo Today 78: 172-179.
42. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103: 2257-2261.
43. Fandy TE, Shankar S, Ross DD, Sausville E, Srivastava RK, (2005) Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 7: 646-657.
44. Shankar S, Davis R, Singh KP, Kurzrock R, Ross DD, et al. (2009) Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice. Mol Cancer Ther 8: 1596-1605.
45. Azmi AS, Philip PA, Aboukameel A, Wang Z, Banerjee S, et al. (2010) Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy. Curr Cancer Drug Targets 10: 319-331.
46. Yamakuchi M, Lowenstein CJ, (2009) MiR-34, SIRT1 and p53: the feedback loop. Cell Cycle 8: 712-715.
47. Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, et al. (2008) Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun 377: 114-119.
48. Koch U, Radtke F, (2007) Notch and cancer: a double-edged sword. Cell Mol Life Sci 64: 2746-2762.
49. Kimura K, Satoh K, Kanno A, Hamada S, Hirota M, et al. (2007) Activation of Notch signaling in tumorigenesis of experimental pancreatic cancer induced by dimethylbenzanthracene in mice. Cancer Sci 98: 155-162.
50. Buchler P, Gazdhar A, Schubert M, Giese N, Reber HA, et al. (2005) The Notch signaling pathway is related to neurovascular progression of pancreatic cancer. Ann Surg 242: 791-800, discussion 800-791.
51. Shankar S, Singh TR, Fandy TE, Luetrakul T, Ross DD, et al. (2005) Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways. Int J Mol Med 16: 1125-1138.
52. Shankar S, Suthakar G, Srivastava RK, (2007) Epigallocatechin-3-gallate inhibits cell cycle and induces apoptosis in pancreatic cancer. Front Biosci 12: 5039-5051.